Unlike activated CD4 + T cells, resting CD4 + T cells are highly resistant to productive HIV-1 infection [1] [2] [3] [4] [5] [6] [7] [8] . Early after HIV-1 entry, a major block limits reverse transcription of incoming viral genomes. Here we show that the deoxynucleoside triphosphate triphosphohydrolase SAMHD1 prevents reverse transcription of HIV-1 RNA in resting CD4 + T cells. SAMHD1 is abundantly expressed in resting CD4 + T cells circulating in peripheral blood and residing in lymphoid organs. The early restriction to infection in unstimulated CD4 + T cells is overcome by HIV-1 or HIV-2 virions into which viral Vpx is artificially or naturally packaged, respectively, or by addition of exogenous deoxynucleosides. Vpx-mediated proteasomal degradation of SAMHD1 and elevation of intracellular deoxynucleotide pools precede successful infection by Vpxcarrying HIV. Resting CD4 + T cells from healthy donors following SAMHD1 silencing or from a patient with AicardiGoutières syndrome homozygous for a nonsense mutation in SAMHD1 were permissive for HIV-1 infection. Thus, SAMHD1 imposes an effective restriction to HIV-1 infection in the large pool of noncycling CD4 + T cells in vivo. Bypassing SAMHD1 was insufficient for the release of viral progeny, implicating other barriers at later stages of HIV replication. Together, these findings may unveil new ways to interfere with the immune evasion and T cell immunopathology of pandemic HIV-1.
Human CD4 + T lymphocytes are the major target cells of HIV-1. Activated CD4 + T cells are highly permissive to infection, but resting CD4 + T cells circulating in peripheral blood and residing in lymphoid organs resist infection. Blocks to infection in these cells occur at different post-entry steps of the viral life cycle [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] .
The accessory lentiviral gene product protein X (Vpx) is encoded by HIV-2 and its related simian immunodeficiency virus (SIV) strains, but not by HIV-1. It is incorporated into virions via an interaction motif in the p6 domain of the structural polyprotein Gag. Notably, delivery of Vpx by virus-like particles or by virion-packaging allows HIV-1 to overcome the early post-entry restriction at the level of reverse transcription in dendritic cells, monocytes and macrophages [11] [12] [13] [14] [15] [16] [17] . Here we asked whether Vpx would allow HIV-1 to infect resting human CD4 + T cells. To efficiently incorporate Vpx into HIV-1 virions, we added a Vpx-interaction motif into the Gag p6 of the CXCR4-tropic HIV-1 strain NL4-3 to generate a replication-competent HIV-1 GFP reporter virus (HIV-1* GFP). Resting CD4 + T cells generally support efficient entry of CXCR4-tropic HIV.
CD4 + T cells purified from peripheral blood of healthy donors were challenged with the engineered HIV-1* GFP virions with or without packaged Vpx. Most CD4 + T cells had a resting phenotype 18 with little or no expression of the activation markers CD25 and CD69, and no indicators of cell proliferation ( Supplementary Fig. 1 ) or cell cycle progression ( Supplementary Fig. 2 ). As expected [2] [3] [4] [5] [6] , resting CD4 + T cells were virtually refractory to infection with HIV-1* GFP ( Fig. 1a; 0.12% GFP + cells). In contrast, infection with HIV-1* GFP virions containing Vpx from SIV mac239 (HIV-1* GFP plus Vpx) yielded >10% of CD25 -CD69 -CD4 + T cells that were GFP + 3 d after challenge (Fig. 1a) with GFP expression reflecting early viral gene expression from reversetranscribed, integrated HIV-1 genomes. Vpx enhanced HIV-1 infection of resting CD4 + T cells in a donor-dependent manner by more than 30-fold (mean: 31.3 ± 8.4; range: 2.2-199.4-fold) (Fig. 1b) . Vpx also increased levels of late reverse transcription products (RU5/gag) (near full-length HIV-1 cDNA) and 2-LTR circles (HIV-1 cDNA byproduct as a marker of successful nuclear entry) ( Fig. 1c and Supplementary Fig. 3 ), which is consistent with an effect of the accessory lentiviral protein on HIV-1 reverse transcription. Furthermore, the infection rate and accumulation of 2-LTR circles in resting CD4 + T cells challenged with HIV-1* GFP virions that had incorporated Vpx proteins of SIV PBj or HIV-2 GH-1 were similar to those observed with HIV-1* GFP virions containing Vpx from SIV mac239 (Fig. 1d-f) , indicating that this is a conserved function of lentiviral Vpx proteins. l e t t e r s npg SAMHD1 is expressed in dendritic cells, monocytes and macrophages, but not in T cell lines, and it has been reported to act as a lineage-specific infection barrier for HIV-1 (refs. 19,20) . Notably, SAMHD1 is targeted by Vpx for CRL4 DCAF1 ubiquitin ligase-dependent proteasomal degradation 17, 19, 20 . In spite of this proposed lineage specificity, we detected high levels of endogenous SAMHD1 mRNA and protein in resting CD4 + T cells that were comparable to those in the monocytic THP-1 cell line (Fig. 2a,b) . Cell activation with phytohemagglutinin (PHA) and interleukin-2 (IL-2) did not affect overall SAMHD1 levels (Fig. 2a,b) . SAMHD1 was also abundantly expressed in explants of human tonsil, a lymphoid tissue targeted by HIV-1 in vivo, where the majority of SAMHD1-expressing cells localized to the perifollicular region and were Ki67 negative, that is, nonproliferating (Fig. 2c) . Co-staining with cell type-specific markers demonstrated SAMHD1 expression predominantly in CD68 + macrophages, DC-SIGN + dendritic cells and CD4 + lymphocytes (data not shown). Nuclear-cytoplasmic fractionation and three-dimensional reconstructions of deconvolution confocal images revealed substantial amounts of SAMHD1 in the nucleus and cytoplasm of resting CD4 + T cells (Fig. 2d,e and Supplementary Video 1), activated CD4 + T cells and macrophages (Supplementary Fig. 5 ). Thus, SAMHD1 might directly deplete levels of dNTPs in the cytoplasm of resting CD4 + T cells where HIV-1 reverse transcription occurs.
To assess the ability of Vpx to degrade endogenous SAMHD1 in resting CD4 + T cells from healthy donors, we co-expressed Myc-tagged SIV mac239 Vpx and a cell surface-exposed GFP variant (Display-GFP; see Online Methods) to facilitate isolation of a homogenous population of viable, nucleofected cells. SAMHD1 pools in both the cytoplasm and the nucleus were depleted after expression of wild-type (WT) Vpx, but not after expression of the CRL4 DCAF1 interaction-deficient mutant Q76A 16, 19 ( Fig. 2f and Supplementary Fig. 6 ), irrespective of the cells' activation status (Supplementary Fig. 6 ). We also detected a potent and Q76-dependent reduction of SAMHD1 levels upon Vpx co-expression by intracellular flow cytometry ( Fig. 2g and Supplementary Fig. 7 ). Low levels of co-expressed GFP and WT Vpx were sufficient to maximally degrade SAMHD1 and diminished intracellular SAMHD1 levels by more than 90% (Fig. 2g, left lower panel) .
Although Vpx enabled early steps of the HIV-1 life cycle, viral progeny were not released from resting CD4 + T cells (Fig. 1g,h) . Virions of the replication-competent HIV-2 strain ROD9 GFP, which naturally encodes Vpx, consistently overcame the early restriction in resting CD4 + T cells in a Vpx-dependent manner, but, similarly to Vpx-carrying HIV-1, they did not lead to the production of new virions (Fig. 1i,j) . The susceptibility of resting CD4 + T cells to the Vpx-carrying HIV-1* GFP reached only ~25% of that of activated CD4 + T cells from the same donors challenged with HIV-1* GFP lacking Vpx, and virion-incorporated Vpx did not significantly enhance the HIV-1 susceptibility of activated cells (P = 0.33; Supplementary Fig. 4) . Thus, Vpx overcomes a block to the early steps of HIV-1 and HIV-2 replication in resting CD4 + T cells, but additional, Vpx-insensitive blocks probably exist at later stages of the viral life cycle. Fig. 8a-c) . Similarly, successful HIV-2 GFP infection correlated with Vpx-dependent degradation of SAMHD1 ( Fig. 1i and Supplementary Fig. 8d) .
In myeloid cells, SAMHD1 hydrolyzes dNTPs, which most likely lowers their concentrations below a threshold required for synthesis of HIV-1 cDNA by reverse transcriptase [21] [22] [23] . To explore this as a mode of restriction for HIV-1 in resting CD4 + T cells, we added pyrimidine and purine deoxynucleosides (dNs) as dNTP precursors to the culture medium. In the absence of Vpx, dNs enhanced the permissivity of resting CD4 + T cells for HIV-1 GFP ninefold (n = 8) over solvent-treated control cells (Fig. 3d) while not affecting the cell cycle or activation status of the cells ( Supplementary Fig. 2a and Supplementary Fig. 9 ). We conducted a side-by-side analysis of the efficacy of virion-packaged Vpx proteins and dN treatment in resting CD4 + T cells from eight donors. The strongly positive correlation of both approaches to augment infection supports a common cellular mechanism that overcomes the HIV-1 restriction (R 2 = 0.72; P = 0.008; Fig. 3e ). Next, we directly determined the effect of T cell activation or of treatment with either dNs or viriondelivered Vpx on intracellular concentrations of dNTPs in resting CD4 + T cells by the single-nucleotide incorporation assay. PHA-and IL-2-mediated activation of CD4 + T cells increased dATP and dTTP concentrations by 2.9-to 7.8-fold (Fig. 3f,g and Supplementary Fig.  10 ), as previously reported 22, 24 . Exogenous dN treatment of resting cells resulted, on average, in 4.4-fold higher cellular dNTP levels. Notably, infection of resting CD4 + T cells with HIV-1* GFP also moderately elevated cellular nucleotide concentrations in a Vpx-dependent manner (1.7-to 2.8-fold, P = 0.05-0.005; Fig. 3f,g and Supplementary Fig.  10 ). This increase was observed despite the relatively low percentage of SAMHD1-depleted cells in this experiment (17% (donor 12) and 31% (donor 13)). Collectively, these results are consistent with the concepts that pools of intracellular dNTPs in resting CD4 + T cells are rate limiting for HIV reverse transcription 8 and that SAMHD1 may be a key regulator of this cellular antiviral state.
To explore the relationship between Vpx-mediated degradation of SAMHD1 and permissivity to HIV-1 in resting CD4 + T cells, we followed both parameters over time at a single-cell level. Whereas infection with HIV-1* GFP had no effect, SAMHD1 was massively depleted in 20-80% of cells 1 d after challenge with HIV-1* GFP plus SIV mac239 Vpx (Fig. 3a,b and Supplementary Fig. 8b ). This degree of depletion was constant until day 3 after infection, when GFP reporter expression indicated proviral integration and early viral gene expression (4.3% of cells in Fig. 3a) . Of note, GFP + cells were detected exclusively within the population of cells containing low amounts of SAMHD1, whereas the residual cell population expressing high amounts of SAMHD1 remained refractory to HIV-1 infection. Virion-incorporated Vpx seemed insufficient to render all resting CD4 + T cells permissive for HIV-1 infection, suggesting either additional Vpx-insensitive limitations for HIV-1 in the post-entry phase 2, 5, 9 or SAMHD1 depletion by Vpx-carrying, but otherwise defective, virions.
SAMHD1 degradation in resting CD4 + T cells was specific to HIV-1* GFP virions containing Vpx; it was observed as early as 6 h after virion challenge and correlated in magnitude with the percentage of GFP + cells (Fig. 3a,b) . The peptidic virion fusion inhibitor T20 or the CXCR4 antagonist AMD3100 inhibited Vpx-dependent depletion of SAMHD1 (Fig. 3c) , demonstrating that this process strictly depends on virus entry and subsequent release of Vpx from disassembled viral capsids. Furthermore, the depletion of SAMHD1 and the enhancement of resting T cell infection by virion-packaged Vpx was abrogated by treatment of cells with the proteasome inhibitors MG132 (Fig. 3c) or ALLN (data not shown) . In (Fig. 4h-j) .
Our results suggest that HIV-1 reverse transcription is actively suppressed in resting human CD4 + T cells, and we identify SAMHD1 as a long-sought cellular factor that is responsible for this restriction. SAMHD1 thus emerges as a ubiquitous and potent barrier to productive HIV-1 infection in dendritic and myeloid cells 17, 19, 20, 22 and also in the large pool of noncycling CD4 + T cells in vivo. Although not excluding additional SAMHD1-dependent mechanisms, the available data are consistent with a scenario in which this restriction is a direct consequence of SAMHD1's enzymatic activity, which limits the availability of dNTPs required for HIV-1 reverse transcription [21] [22] [23] . Regulation of deoxynucleotide levels in resting cells by SAMHD1 may have evolved to protect T helper cells from retroviral insult without the risk of disrupting the homeostasis of these noncycling cells. Therapeutic manipulation of intracellular dNTP pools thus emerges as a potential antiretroviral strategy. Given the overall potency of virus-encoded SAMHD1 antagonists, such as Vpx, to expand the target cell population of HIV-1 to noncycling cells, it seems surprising that they were lost in lentiviral evolution 28, 29 . This indicates that overcoming SAMHD1 restriction in these types of cells may in fact carry significant adverse consequences for pandemic HIV-1 and that the abortive SAMHD1-restricted To directly probe the ability of SAMHD1 to restrict HIV-1 infection in resting CD4 + T lymphocytes from healthy donors, we used two RNAi strategies to silence its expression 25, 26 . We activated primary CD4 + T cells to allow effective siRNA delivery by nucleofection or transduction with lentiviral vectors carrying shRNAs. We gradually reduced IL-2 concentrations and analyzed the cells for HIV-1 permissivity once they returned to a quiescent and HIV-1-restrictive state, typically by day 14 after activation (see also Supplementary Figs. 11a  and 12a) . We classified post-activation CD4 + T cells as resting on the basis of three criteria: (i) their lack of CD25 and CD69 expression, (ii) their lack of proliferation markers and (iii) their resistance to HIV-1 infection after treatment with control siRNA (Con) (Fig. 4a-g and Supplementary Fig. 11b-d) . Silencing of SAMHD1 with three independent siRNAs markedly reduced cellular SAMHD1 levels (Fig. 4d-g  and Supplementary Fig. 11e ) and rendered post-activation resting CD4 + T cells from multiple donors (n = 6) permissive to HIV-1 infection (Fig. 4b-g and Supplementary Fig. 11b-d) . The enhancement of HIV-1 infection ranged from 5.1-to 18.6-fold, depending on the donor and knockdown efficiency, corresponding to 3.6-15.3% infected GFP + cells (Fig. 4d-g and Supplementary Fig. 11d ). We observed a similar but slightly less potent increase in HIV-1 infection in postactivation resting CD4 + T cells when SAMHD1 was silenced by shRNA transduction (Supplementary Fig. 12b-d) of two targeting sequences that are distinct from those of the siRNAs used. Thus, depletion of cellular SAMHD1 by RNAi is sufficient to enhance the permissiveness of resting CD4 + T cells for HIV-1 infection. Finally, we wanted to determine whether resting CD4 + T cells with a nonsense mutation in 
METHODS
Methods and any associated references are available in the online version of the paper. Virus production. Sucrose cushion-purified HIV-1 virus stocks were produced as previously described 40 . HIV-1* GFP virus stocks, carrying virion-packaged Vpx, were produced by co-transfection of the proviral HIV-1* GFP DNA and the indicated Vpx expression constructs 36 . DNase treatment of virus stocks was performed as previously reported 41 .The infectious titer was determined in a standardized TZM-bl infectivity assay 42 .
Note: Supplementary information is available in the online version of the paper.
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HIV-1 infection.
If not stated otherwise, resting primary CD4 + T cells were infected with identical infectious units (10 5 TZM-bl IU per 10 6 cells corresponding to a multiplicity of infection (MOI) of 0.1) of HIV-1 GFP or HIV-1*GFP ± Vpx using spin-infection for 90 min at 800 r.p.m. at room temperature. The medium was exchanged 4-6 h after infection. Three days later, cells were stained for CD25 and CD69 expression, fixed in 4% PFA in PBS and analyzed on a FACSCalibur. For the experiment shown in Figure 4h Cell fractionation. For nuclear-cytoplasmic fractionation 43 , resting and activated CD4 + T cells (2 × 10 7 ) or macrophages were first washed in cold PBS, followed by incubation in a hypotonic lysis buffer (10 mM HEPES, pH 7.9; 1.5 mM MgCl 2 ; 10 mM KCl; 0.5 mM DDT) containing a protease inhibitor cocktail (SigmaAldrich). Next, an aliquot was taken representing the whole cell lysate (WCL). After mechanical disruption of the plasma membrane by douncing, cells were spun twice at 1,700 r.p.m. for 10 min to separate the cytoplasmic and nuclear fraction. Next, an aliquot was taken representing the cytoplasm. The remaining nuclear pellet was resuspended in buffer S1 (0.25 mM sucrose; 10 mM MgCl 2 ) containing protease inhibitors and overlaid with buffer S3 (0.88 mM sucrose; 0.5 mM MgCl 2 ). After centrifugation (3,000 r.p.m., 15 min), the nuclear pellet was resuspended in RIPA buffer and briefly sonicated, and the nuclear fraction was harvested. Aliquots of the respective fractions were mixed with 2× SDS sample buffer and analyzed by immunoblotting.
Immunostaining of tonsil sections. Immunoenzyme staining of paraffinized tonsil tissue was performed as reported 44 . Briefly, antigen retrieval was achieved by steam-cooking slides in 10 mM citrate buffer (pH 6.1; Dako) for 30 min. A solution of 10% Earle's balanced salt solution (EBSS, Sigma-Aldrich) supplemented with 1% HEPES, 0.2% BSA and 0.1% saponin (all from Sigma-Aldrich), pH 7.4, was used as a washing, permeabilization and staining buffer. The rabbit anti-SAMHD1 antibody (1:100) was added and incubated overnight. As secondary reagent biotinylated donkey anti-rabbit IgG (1:200; Jackson ImmunoResearch) was applied for 30 min at room temperature, followed by incubation with an avidin-containing ABC-AP Kit (Vectastain; Vector Laboratories). Naphthol AS-biphosphate (Sigma-Aldrich) with New Fuchsin (Merck) was used as the substrate for alkaline phosphatase (AP). Images were acquired on an Olympus BX45 microscope. For double immunofluorescence staining, paraffinized tonsil tissue sections, following antigen retrieval, were incubated overnight with primary antibodies (rabbit anti-SAMHD1 (1:100, Proteintech), mouse anti-Ki67 (1:800, GeneTex)). As secondary reagent, a biotinylated donkey anti-mouse IgM antibody (1:100, Zymed) was applied for 30 min at room temperature, followed by incubation with fluorescently labeled antibodies donkey anti-rabbit IgG Alexa488 (1:2,000, Invitrogen) and streptavidin-Cy3 (1:800, Jackson ImmunoResearch). Images were acquired with an Olympus IX81 microscope.
Immunofluorescence microscopy and three-dimensional reconstruction.
Resting and activated CD4 + T cells as well as macrophages were placed on poly-l-lysine-coated cover glasses and fixed for 30 min with 3% paraformaldehyde in PBS. After permeabilization with 0.1% Triton X-100 in PBS, cells were incubated with 2% BSA in PBS for 30 min. Next, cells were stained with rabbit Resting CD4 + T cells were cultured at a density of 2 × 10 6 cells per ml in RPMI-1640 medium (Gibco) supplemented with 10% heatinactivated fetal calf serum, glutamine (2 mM) and antibiotics (100 U/ml penicillin, 100 mg/ml streptomycin). For T cell activation, PHA-P (5 µg/ml) or PHA-L (2 µg/ml) (both from Sigma-Aldrich) were added to the culture medium for 2-3 d together with IL-2 (20 or 100 IU/ml) (Biomol). To obtain post-activation resting T cells, the IL-2 concentration was gradually decreased as indicated in Supplementary Figures 11a and 12a . The human cell lines THP-1 and Jurkat were cultivated as reported 17, 33 . Human macrophages were derived from PBMCs and cultivated as previously described 32 .
The following fluorochrome-conjugated antibodies were used: anti-human CD3 (clone SK7 The following dNs were purchased from Sigma-Aldrich: 2-deoxyadenosine, 2′-deoxyguanosine, thymidine and 2′-deoxycytidine hydrochloride. dNs were dissolved in either RPMI (pH 4.1) or RPMI (pH 7.4; 2′-deoxycytidine hydrochloride). MG132 and ALLN (Sigma-Aldrich) were used as reported 34 . T20 (enfuvirtide, Roche) and efavirenz (Bristol-Myers Squibb) were used as described 35 . AMD3100 was a gift from H.-G. Kräusslich. The p24 ELISA (Innotest HIV Antigen mAB, Innogenetics) and p27 ELISA (SIV p27 antigen capture assay, Advanced Bioscience) were performed according to the manufacturer's protocol.
Plasmids. The infectious HIV-1 GFP proviral clone is based on HIV-1 NL4-3 and contains EGFP in the 5′-region of nef and a polypurine track 3′ of EGFP followed by the remaining 3′-LTR sequence (gift from J. Münch). The infectious WT HIV-2 GFP WT and DVpx proviral clones, based on pROD9-∆Env-GFP and pROD9-∆Env-delVpx-GFP from M. Emerman, were generated by reintroduction of Rod9 Env. The Vpx-binding motif DPAVDLL from SIVmac Gag was introduced into p6 of HIV-1 GFP (HIV-1* GFP) by overlapping PCR using the SpeI and SbfI sites of HIV-1 GFP 14 . Vpx expression constructs used were: pcDNA3.1Vpx SIV mac239 -Myc (WT and Q76A) 36, 37 , pcDNA3.1VpxSIV PBj 38 and pEF-FVpxHIV-2 GH1 (gift from M. Fujita). pDisplay-GFP was from B. Müller. Figure 4h -j, to detect intracellular SAMHD1 in resting CD4 + T cells, the cells were co-stained with a surface stain antibody mixture of FITC-labeled anti-CD3, PE-labeled anti-CD4, BD Horizon V450-labeled anti-CD25 and BD Horizon V450-labeled anti-CD69 (all 1:20, from BD Bioscience) at room temperature for 1 h. After two washing steps, the samples were analyzed on a BD FACS LSR II SORP instrument.
PCR analyses. TaqMan-based quantifications of HIV-1 2-LTR circles (HIV-1 cDNA byproduct as a marker of successful nuclear entry) in DNA extracts from infected resting CD4 + T cells were performed as described 35, 45 . The TaqManbased quantification of RU5/gag (near full-length HIV-1 cDNA) was established and validated based on the primer regions chosen by Zack et al. 6 . The PCR conditions for RU5/gag were: 50 °C for 2 min, 95 °C for 10 min with a denaturation step at 95 °C for 15 s, an annealing step at 55 °C for 30 s, and elongation step at 72 °C for 1 min for 40 cycles. Data acquisition was performed at the elongation step. RNA extraction and TaqMan-based mRNA quantification of SAMHD1 (Applied Biosystems: assay no. Hs00210019_m1) and RNaseP (Applied Biosystems: TaqMan RNase P Control Reagents Kit (4316844), endogenous reference control) were performed as reported 46 . Relative mRNA levels were calculated as 1/ DC t and are presented relative to results obtained for THP-1 cells.
Cell cycle analysis. Cell cycle analysis was performed by staining DNA and RNA of resting and activated CD4 + T cells with 7-amino-actinomycin-D (7-AAD) and pyronin Y, respectively, as previously described 47 .
